Table 1.
Substrates of TRIM21 involved in cancer treatments.
| Model | Substrate | Function | Manner | Reference |
|---|---|---|---|---|
| Hepatoma cell lines | HBx protein | HBV replication suppression | (72) | |
| Cervical cancer cells | IFI16 | Cell pyroptosis inhibition and self-escape from immune surveillance | K33-linked | (73, 74) |
| HCT116 and U87 cells | CLASPIN | Replication fork instability and tumorigenesis | K63-linked | (108) |
| Pancreatic and colon cancer cells | Par-4 | Increased cisplatin resistance | (110) | |
| Osteosarcoma cells | TXNIP | Decreased p21 expression | (105) | |
| Colorectal cancer cells | Oct-1 | Sensitive to chemoradiation | (122) | |
| Primary mouse hepatocytes, hepatoma cells | PXR | Impaired drug–drug interactions | (125) | |
| 293T cells | p62 | Nrf2 redox pathway inhibition the cell death induction | K63-linked | (130) |
| Bladder cancer cells | PTMA | p62 and Nrf2 expression inhibition | (134) | |
| Nasopharyngeal carcinoma | SGSM1 | MAPK pathway activation and metastasis | Lys349 Lys352 | (136) |
| Breast cancer cells | SET7/9, SALL4 | Tumorigenesis inhibition | Lys190 in SALL4 | (137, 138) |
| Breast cancer cells | Snail | EMT inhibition | (139) | |
| Breast cancer cells | TβRII | TGF-β signaling pathway inhibition | (140) | |
| Lung cancer cells | C/EBPa | Cells proliferation inhibition | (141) | |
| Glioma cancer cells | CREB | Tumorigenesis inhibition | (142) |
Multiple ubiquitination substrates of TRIM21 have been identified involved in cancer treatments.